Lung Cancer PrECOG M022097

March 13, 2013

Location: The Hospital of Central Connecticut

An Open-Label, Randomized, Phase IIIB Trial Evaluating The Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) After First-Line Treatment with Bevacizumab Plus a Platinum Doublet-Containing Chemotherapy.